OVID · NASDAQ
Ovid Therapeutics (OVID) Stock Price & Fundamentals
Ovid Therapeutics (OVID) closed at $780.40 on Oct 9, 2026, up 0.63% from the previous close of $775.51.
Share price, past year
1Y +1.74%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $780.40 |
| Sep 30, 2026 | $748.35 |
| Aug 31, 2026 | $778.03 |
| Jul 31, 2026 | $747.21 |
| Jun 30, 2026 | $750.12 |
| May 29, 2026 | $793.27 |
| Apr 30, 2026 | $772.83 |
| Mar 31, 2026 | $747.30 |
| Feb 27, 2026 | $740.99 |
| Jan 30, 2026 | $717.95 |
| Dec 31, 2025 | $701.36 |
| Nov 28, 2025 | $715.99 |
| Oct 31, 2025 | $763.21 |
Key statistics
- Market cap
- $144.18B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $1.58M
- Net income (TTM)
- −$34.49M
- Shares outstanding
- 184.8M
- Dividend yield
- —
- 52-week range
- $685.12 – $802.58
Ovid Therapeutics's market cap is $144.18B, based on a share price of $780.40 and 184.8M shares outstanding as of Jun 30, 2026.
Financials
Ovid Therapeutics reported revenue of $7.25M for fiscal 2025, up 1,181.27% from fiscal 2024.
Ovid Therapeutics reported a net loss of $17.41M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $7.25M | +1,181.3% | −$17.41M | −240.1% | — | −$38.33M |
| FY2024ended Dec 31, 2024 | $566.00K | +44.4% | −$26.43M | −4,670.1% | — | −$56.03M |
| FY2023ended Dec 31, 2023 | $392.00K | −73.9% | −$52.34M | −13,351.8% | −$0.74 | −$45.82M |
| FY2022ended Dec 31, 2022 | $1.50M | −99.3% | −$54.17M | −3,604.7% | −$0.77 | −$56.45M |
| FY2021ended Dec 31, 2021 | $208.38M | +1,551.6% | $122.83M | 59.0% | $1.76 | $118.43M |
| FY2020ended Dec 31, 2020 | $12.62M | — | −$81.04M | −642.3% | −$1.39 | −$51.71M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $733.00K | −$15.01M | — |
| Q1 FY2026ended Mar 31, 2026 | $0.00 | −$16.99M | — |
| Q4 FY2025ended Dec 31, 2025 | $718.00K | $9.66M | — |
| Q3 FY2025ended Sep 30, 2025 | $132.00K | −$12.16M | — |
| Q2 FY2025ended Jun 30, 2025 | $6.27M | −$4.68M | — |
| Q1 FY2025ended Mar 31, 2025 | $130.00K | −$10.24M | — |
| Q4 FY2024ended Dec 31, 2024 | $76.00K | −$9.25M | — |
| Q3 FY2024ended Sep 30, 2024 | $173.00K | −$14.01M | −$0.20 |
Company profile
- Name
- Ovid Therapeutics Inc.
- Ticker
- OVID
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 441 Ninth Avenue, 14th Floor, New York, NY 10001
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001636651
Recent SEC filings
- Aug 13, 2026
- Aug 13, 2026
- Jul 8, 2026
- Jun 11, 2026
- Jun 3, 2026
- May 12, 2026
- May 12, 2026
- Apr 20, 2026
Frequently asked questions
What is Ovid Therapeutics's stock price?
Ovid Therapeutics (OVID) closed at $780.40 on Oct 9, 2026, up 0.63% from the previous close of $775.51.
What is Ovid Therapeutics's market cap?
Ovid Therapeutics's market cap is $144.18B, based on a share price of $780.40 and 184.8M shares outstanding as of Jun 30, 2026.
How much revenue does Ovid Therapeutics make?
Ovid Therapeutics reported revenue of $7.25M for fiscal 2025, up 1,181.27% from fiscal 2024.
Does Ovid Therapeutics pay a dividend?
Ovid Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Ovid Therapeutics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures